Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2
J. Campagna, B. Jagodzinska, P. Alvarez, C. Yeun, P. Spilman, K. M. Enquist, W. Cohn, P. Fajtov, A. J. O'Donoghue, V. Arumugaswami, M. M. H. Li, R. Damoiseaux, V. John
The paper identifies eltrombopag as a PLpro inhibitor that can be repurposed for SARS-CoV-2 treatment, effective in combination with Mpro inhibitors.
bioRxiv · Jul 18, 2022Microbiology